Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q1- Text added to 2023 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
advisory, American, Antonio, Australian, causal, chat, deducting, Diaz, driven, elevated, epithelial, EVFF, EVs, fireside, Friend, Gordon, immune, inference, light, lowered, Maxim, neurodegeneration, NfL, payable, PDUFA, Prescription, prognostic, Science, streaming, Thereof, Thoracic, transforming, translational, Trejo, vivo, Weizmann
Removed:
AAN, abstract, acted, activated, Advancing, allele, ATMP, BALF, Berry, breaking, CA, CDER, Chair, Christopher, Cleveland, CMCF, CMSC, Cohen, Component, concomitant, Consortium, Division, Edinburgh, EPO, experiment, Family, FVC, genetic, Harbor, IIA, influence, investigator, Jeffrey, Jonathan, JPO, Katz, Kern, Kim, leveraging, line, Lock, MA, Maryland, Mellen, MGH, MHSc, modulator, monocular, mononuclear, multidisciplinary, Network, neurite, neuroblastoma, Northeast, outgrowth, PBMC, peripheral, PhD, Ralph, Relationship, Scholar, Scotland, Sidney, Siponimod, Spector, Stanford, symposium, Thacker, USA, Winthrop
Valuein 2023 Q1 filing- Value in 2023 Q2 filing
Original filings
Filing view